Results 21 to 30 of about 2,138,197 (387)
Advances in Hematology, 2012 Aggressive B-cell lymphomas (ABLs) are a group of B-cell malignancies, that is, a relatively common form of cancer across the world. This issue on aggressive B-cell lymphomas compiles 12 exciting manuscripts, most of which are very meticulously performed reviews of the available current literature.
Naresh KN +3 more
openaire +4 more sources
Journal of Clinical Oncology, 2021 PURPOSE Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin
M. Hutchings +22 more
semanticscholar +1 more source
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. [PDF]
, 2018 Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of ...
Aliberti S +24 more
core +1 more source
New England Journal of Medicine, 2002 BACKGROUND The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival.
A. Rosenwald +39 more
semanticscholar +1 more source
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
New England Journal of Medicine, 2021 BACKGROUND Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy.
Michael R. Bishop +40 more
semanticscholar +1 more source
Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study
Diagnostics, 2023 Background: Extranodal non-Hodgkin lymphoma (NHL) is more prevalent in the gastrointestinal (GI) tract than in other sites. This study aimed to determine the endoscopic characteristics of primary gastrointestinal non-Hodgkin lymphomas.
Quang Trung Tran +7 more
doaj +1 more source
Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures.
Cancer Discovery, 2021 Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogenous disease. Transcriptomic and genetic characterization of DLBCL have increased the understanding of its intrinsic pathogenesis and provided potential therapeutic targets ...
N. Kotlov +20 more
semanticscholar +1 more source
Primary mediastinal lymphoma: diagnosis and treatment options. [PDF]
, 2014 Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a
DI ROCCO, Alice +4 more
core +1 more source
Blood, 2021 Corticosteroids are used to treat the acute complications of chimeric antigen receptor (CAR) T-cell therapy. Strati et al examine the impact of corticosteroids on patient outcomes following CAR T-cell therapy for large B-cell lymphoma.
P. Strati +29 more
semanticscholar +1 more source
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]
, 2017 Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Brennan, Cameron W. +41 more
core +2 more sources